The Preferred Biotech Resource in Asia-Pacific
Vol 19, No 07, July 2015
Biotech in China
Kh-biotech cover

Featured
Interviews

Eye on China

Columns

Conferences ListingConferences
Listing

e-alerts
Pharma Sales
INSIDE INDUSTRY
Anergis expands management team
Anergis, a company developing breakthrough allergy vaccines for fast and safe allergen-specific immunotherapy, announced the expansion of its management team. With the appointments of Gilles Della Corte as Director of Clinical Development and Eva Castagnetti as Director of Product Development, the company has significantly strengthened its late-stage drug development expertise.

Gilles Della Corte, MD, brings to Anergis extensive expertise in global clinical development. In the past 22 years, he worked both for pharmaceutical companies, including Rhone-Poulenc Rorer, Servier, Solvay Pharma, Serono and Merck Serono, and for CROs where he held various senior positions in Research and Development. He has significant experience with all stages and aspects of clinical drug development ranging from Phase I to Phase IV. A cardiologist and pharmacologist by training, Gilles also holds diplomas in statistics and clinical trial methodology. 

Eva Castagnetti, PhD, has several years of experience in both technical and business management  functions in the biopharmaceutical industry with Lonza, Senn Chemicals and Rapid Pharmaceuticals. She has been responsible for the development and production of Active Pharmaceutical Ingredients (peptides) in early to late clinical phases, gaining comprehensive experience of the regulatory and quality requirements in the development of new pharmaceutical products. Eva obtained her PhD in organic chemistry in 2001 from the University of Lausanne/EPFL and spent two years as a postdoctoral fellow at the Massachusetts Institute of Technology (Cambridge/Boston) and at the ETH Zurich.

“Anergis has evolved into a clinical-stage company with several product candidates. We expect to report Phase II results of our large, randomized, controlled European trial of AllerT in Q3, 2013. Anergis’ lead-product AllerT, a vaccine to treat birch pollen allergies, is in Phase II clinical development. AllerR, its second vaccine candidate for the treatment of patients with allergy to ragweed pollen, has recently reached important preclinical milestones and received positive feedback from the U.S. FDA for the subsequent clinical development program in June 2012.

With the appointments of Gilles Della Corte and Eva Castagnetti, Anergis has gained significant product and clinical development expertise, which will both be essential for the future clinical development of AllerT as well as for our expanding product pipeline,” said Vincent Charlon, CEO of Anergis.

Click here for the complete issue.